Author of

• 18975

  +

  P3.01 - Advanced NSCLC (ID 621)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23865

    +

    P3.01-006 - Osimertinib in Pretreated EGFR T790M-Positive Non-Small Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis (ID 7905)

    09:30 - 09:30  |  Author(s): Y. Chen
    • Abstract
    • Slides

    Background:
    Leptomeningeal carcinomatosis (LC) is a detrimental complication of non-small cell lung cancer (NSCLC). Osimertinib is the current standard therapy for pretreated EGFR T790M-positive NSCLC patients. However, the efficacy of osimertinib for these patients with LC is unknown.
    
    Method:
    Retrospective case series of 5 patients with pretreated EGFR T790M-positive NSCLC who developed LC and received osimertinib therapy in an Expanded Access Program was reviewed. We evaluated the clinical outcomes of these patients.
    
    Result:
    Four female patients and one male patient (age, range 51-67) with EGFR T790M-positive NSCLC and LC received osimertinib therapy at a starting dose of 80 mg/day. EGFR T790M mutation was detected in three re-biopsied specimens and two plasma samples. Four patients had Eastern Cooperative Oncology Group performance status (PS) ≧ 2. One patient received whole-brain radiotherapy after commencing osimertinib therapy. Osimertinib dose escalation to 160 mg/day or 160 mg every other day was administered to 3 patients who did not respond to standard dose therapy. Radiologically decreased leptomeningeal enhancement was seen in 3 out of 4 evaluable patients, and improvement of clinical symptoms was recorded in 2 patients. Two patients died of aspiration pneumonia, and one died of hypoxic respiratory failure of unknown cause. Osimertinib therapy is ongoing in two patients at 80 mg/day for 9 and 10 months, respectively, with good tolerability.
    
    Conclusion:
    Osimertinib is well tolerated even in patients with poor PS. Clinical benefits were seen in some patients, and the optimal dose should be explored.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.